APP — Amyloid Precursor Protein

Migration, Crosslink

📖

APP — Amyloid Precursor Protein

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-app

📖 Wiki Page

gene2551 wordssynced 2026-04-02

APP — Amyloid Precursor Protein

Pathway Diagram

...

APP — Amyloid Precursor Protein

Pathway Diagram

Mermaid diagram (expand to render)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APP — Amyloid Precursor Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>APP</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Amyloid Precursor Protein</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>21q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/351" target="_blank">351</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142192" target="_blank">ENSG00000142192</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/104760" target="_blank">104760</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P05067" target="_blank">P05067</a></td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>770 amino acids (APP770 isoform)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~110 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, highest in brain</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy), [Down Syndrome](/diseases/down-syndrome)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1979 edges</a></td>
</tr>
</table>

APP — Amyloid Precursor Protein

Overview

APP (Amyloid Precursor Protein) is a gene located on chromosome 21q21.3 that encodes a type I transmembrane protein critical for neuronal health and central to the pathogenesis of Alzheimer's disease (AD) and related neurodegenerative disorders[@kang1987]. The APP protein is sequentially cleaved by alpha-, beta-, and gamma-secretases through two mutually exclusive proteolytic pathways, generating various peptide fragments including amyloid-beta (Aβ) peptides when processed via the amyloidogenic pathway[@citron1992].

The amyloid cascade hypothesis, first proposed in 1992, posits that accumulation of Aβ peptides in the brain triggers a cascade of pathological events including neurofibrillary tangle formation, synaptic loss, and neuronal death[@hardy1992]. While this hypothesis has undergone significant refinement over decades of research, APP and its proteolytic processing remain central to AD therapeutic strategies.

APP is one of the most intensively studied genes in neuroscience due to its pivotal role in neurodegeneration. Triplication of APP on chromosome 21 in Down syndrome leads to early-onset AD pathology, providing human genetic evidence for APP's causal role in amyloid deposition[@head2016].

Molecular Biology of APP

Gene Structure and Isoforms

The APP gene spans approximately 350 kb and consists of 18 exons. Alternative splicing generates multiple isoforms:

APP770: Full-length isoform containing the KPI domain and exon 15, widely expressed
APP751: Includes KPI domain, expressed in most tissues
APP695: Neuron-specific isoform lacking KPI domains, predominant in brain

The APP protein contains several functional domains:

Extracellular domain:

N-terminal signal peptide
Copper-binding domain (CuBD)
KPI domain (Kunitz-type protease inhibitor)
Amyloid-beta (Aβ) region (residues 681-770)

Transmembrane domain:

Single pass transmembrane helix
Site of gamma-secretase cleavage

Cytoplasmic domain:

Intracellular signaling domain
Tyrosine-based sorting motifs
C-terminal interaction sites

APP Processing Pathways

APP undergoes proteolytic processing through two mutually exclusive pathways[@vassar1999][@wolfe2009]:

Amyloidogenic Pathway (Aβ-Generating)

This pathway generates Aβ peptides through sequential cleavage:

Beta-secretase (BACE1) cleavage: BACE1 (Beta-site APP-cleaving enzyme 1) cleaves APP at the N-terminus of the Aβ domain (Met-681), generating the membrane-bound C-terminal fragment C99 and soluble APPβ (sAPPβ)[@vassar1999]

Gamma-secretase cleavage: The presenilin-containing gamma-secretase complex (comprising PSEN1 or PSEN2, PEN-2, APH-1, and NCT) cleaves C99 within the transmembrane domain at multiple sites, releasing Aβ peptides of varying lengths[@wolfe2009]

The Aβ40 peptide (40 amino acids) is the predominant species generated (~90%), while Aβ42 has greater aggregation propensity and is the primary constituent of amyloid plaques. Longer species (Aβ43, Aβ45) are also produced but less abundant.

Non-Amyloidogenic Pathway (Aβ-Preventing)

This pathway precludes Aβ formation:

Alpha-secretase cleavage: ADAM10 (A Disintegrin and Metalloproteinase domain 10) cleaves APP within the Aβ domain (between Lys-16 and Leu-17 of Aβ), generating sAPPα and the C-terminal fragment C83[@lammich1999]

Gamma-secretase cleavage: Subsequent gamma-secretase cleavage of C83 releases the non-amyloidogenic p3 fragment

This pathway is considered neuroprotective and is the target of some therapeutic strategies aimed at shifting APP processing away from amyloidogenic toward non-amyloidogenic processing.

Normal Physiological Functions

Beyond its central role in AD pathogenesis, APP serves important normal physiological functions[@mller2014]:

Synaptic Function and Plasticity

APP is highly expressed in synaptic compartments and participates in synaptic formation, maintenance, and plasticity:

Regulates synaptic structure and function
Involved in long-term potentiation (LTP)
Mediates excitatory synaptic transmission
Supports dendritic spine morphology
Functions as a synaptic adhesion molecule

Neuronal Development

During brain development, APP regulates:

Neuronal migration
Axonal growth and guidance
Synaptogenesis
Myelin formation
Neuronal survival through neurotrophic signaling

Metal Ion Binding and Homeostasis

APP binds copper (Cu+) and zinc (Zn2+) ions through its N-terminal copper-binding domain:

Plays roles in metal ion homeostasis
Antioxidant responses through copper sequestration
Cellular redox regulation

Cell Adhesion and Signaling

APP functions as a synaptic adhesion molecule, participating in:

Neuronal survival signaling through interaction with Frizzled receptors
Synaptic contact formation
Membrane protein interactions
Regulation of cell proliferation

Peripheral Tissue Functions

In non-neural tissues, APP is expressed at lower levels and functions in:

Platelet activation and wound healing
Muscle development
Iron export (in conjunction with ferroportin)

APP in Alzheimer's Disease

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis remains foundational to AD pathogenesis research[@hardy1992][@selkoe2024]:

Genetic mutations causing increased Aβ production (APP, PSEN1, PSEN2) lead to familial AD

Aβ oligomerization and plaque formation ensue

Synaptic dysfunction and neuronal loss follow

Tau pathology develops as a downstream consequence

While the hypothesis has been refined—acknowledging that soluble Aβ oligomers rather than plaques may be the toxic species—the central role of APP/Aβ in AD remains well-established.

APP Mutations in Familial AD

Over 50 pathogenic APP mutations cause autosomal dominant Alzheimer's disease (ADAD)[@ryman2015]:

| Mutation | Location | Effect |
|----------|----------|--------|
| Swedish (KM670/671NL) | Beta-secretase site | Increases Aβ production 3-6 fold |
| London (V717I) | Gamma-secretase site | Shifts Aβ42/Aβ40 ratio toward Aβ42 |
| Arctic (E693G) | Aβ domain | Enhances Aβ protofibril formation |
| Flemish (A692G) | Alpha-secretase site | Increases Aβ production |
| Iowa (D694N) | Aβ domain | Promotes aggregation |

These mutations provide direct genetic evidence linking APP to AD pathogenesis and have been instrumental in developing therapeutic strategies.

Down Syndrome and APP

Individuals with Down syndrome (trisomy 21) develop early-onset AD pathology by age 40-50 due to APP gene dosage effect[@head2016]:

APP triplication leads to approximately 1.5-fold increase in Aβ production
Aβ deposition begins in the third decade of life
Nearly all individuals with DS develop AD-type pathology by age 60
Provides human genetic model for APP-induced neurodegeneration

APP in Other Neurodegenerative Diseases

Cerebral Amyloid Angiopathy (CAA)

APP mutations cause hereditary cerebral amyloid angiopathy characterized by[@revesz2019]:

Aβ deposition in cerebral blood vessel walls (predominantly Aβ40)
Recurrent hemorrhagic strokes
Cognitive decline
Dutch type (E693Q) and Iowa type (D694N) mutations

Parkinson's Disease

Emerging evidence links APP to [Parkinson's disease](/diseases/parkinsons-disease)[@tsao2022]:

Increased APP expression in PD substantia nigra
Aβ colocalization with Lewy bodies in some cases
APP promoter variants associated with PD risk
Interactions between APP processing and alpha-synuclein pathology

Traumatic Brain Injury

Chronic traumatic encephalopathy (CTE) shows[@wang2024]:

Increased APP expression following head trauma
Aβ accumulation in athletes with repetitive brain injury
May represent a second hit that accelerates neurodegeneration

Other Disorders

Huntington's Disease: Altered APP processing may contribute to neurodegeneration
Amyotrophic Lateral Sclerosis: APP expression changes in motor neurons
Frontotemporal Dementia: Some cases show Aβ comorbidity

Therapeutic Targeting

Secretase Modulators

Beta-secretase (BACE1) inhibitors: Multiple BACE1 inhibitors reached clinical trials but were discontinued due to adverse effects[@haass2022]:

Verubecestat: Discontinued due to cognitive worsening
Lanabecestat: Halted for safety concerns
Umibecestat: Stopped for cognitive decline

The failure of BACE1 inhibitors highlights the importance of APP's normal physiological functions and suggests that complete inhibition may be deleterious.

Alpha-secretase activators: ADAM10 activation represents a therapeutic approach to shift APP processing toward the non-amyloidogenic pathway, though clinical development remains challenging.

Anti-Aβ Immunotherapy

Active and passive immunization approaches targeting Aβ have shown clinical success[@van2023]:

Monoclonal antibodies:

[Lecanemab](/therapeutics/lecanemab): FDA-approved, reduces brain amyloid
[Donanemab](/therapeutics/donaneumab): FDA-approved, removes plaques
Aducanumab: FDA-approved, controversial efficacy

Mechanisms:

Promote amyloid plaque clearance
Reduce soluble Aβ oligomers
May modulate microglial activation

Adverse effects:

ARIA (Amyloid-Related Imaging Abnormalities)
Amyloid-related edema (ARIA-E)
Microhemorrhages (ARIA-H)

APP-Targeting Approaches

Emerging strategies include:

Small molecules modulating APP trafficking
Gene therapy approaches
RNA interference targeting APP expression
Vaccine development targeting multiple Aβ species

Disease-Modifying Strategies

Given the central role of APP/Aβ, several approaches aim to intervene at different points:

| Target | Strategy | Status |
|--------|----------|--------|
| Aβ production | BACE1 inhibitors | Discontinued |
| Aβ aggregation | Aggregation inhibitors | Preclinical |
| Aβ clearance | Immunotherapy | FDA approved |
| APP expression | Gene therapy | Investigational |

APP Family and Splice Variants

The APP gene family includes:

APP: The canonical gene discussed here
APLP1 (Amyloid Precursor-Like Protein 1)
APLP2 (Amyloid Precursor-Like Protein 2)

APP undergoes alternative splicing, generating multiple isoforms:

APP695: Neuron-specific, lacking KPI domain
APP751: Including KPI domain
APP770: Full-length with both KPI and exon 15

APLP family members share functional domains but lack the Aβ sequence and cannot generate amyloid peptides.

Brain Expression Pattern

APP exhibits region-specific expression throughout the brain:

| Brain Region | Expression Level | Cell Type |
|--------------|-----------------|-----------|
| Cerebral Cortex | Very High | Pyramidal neurons |
| Hippocampus | Very High | CA1-CA3 pyramidal cells |
| Basal Forebrain | High | Cholinergic neurons |
| Cerebellum | Moderate | Purkinje cells |
| Substantia Nigra | Moderate | Dopaminergic neurons |

Expression data from the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=APP) confirms highest expression in cortical and hippocampal regions vulnerable to AD pathology.

Single-Cell Expression

APP is expressed in multiple neuronal and glial cell types:

Glutamatergic neurons (highest)
GABAergic neurons
Oligodendrocyte precursors
[Astrocytes](/cell-types/astrocytes) Microglia (lower levels)

Interaction Network

APP interacts with numerous proteins relevant to neurodegeneration:

| Partner | Interaction Type | Relevance |
|---------|-----------------|-----------|
| BACE1 | Proteolytic cleavage | Aβ generation |
| ADAM10 | Proteolytic cleavage | Non-amyloidogenic |
| PSEN1/2 | Proteolytic cleavage | Gamma-secretase |
| Frizzled | Signaling | Wnt modulation |
| Cu/Zn ions | Metal binding | Redox regulation |
| LDL receptor family | Endocytosis | Aβ clearance |

Biomarker Potential

APP Metabolites as Biomarkers

APP processing products serve as diagnostic biomarkers:

CSF biomarkers:

sAPPα and sAPPβ: Markers of alpha- and beta-secretase activity
Aβ42/Aβ40 ratio: Diagnostic for AD
Total tau and phospho-tau: Neurodegeneration markers

Imaging biomarkers:

Amyloid PET: Visualizes plaque burden
Florbetapir, Florbetaben: FDA-approved tracers

Blood-based biomarkers:

Aβ42/Aβ40 ratio: Emerging blood test
p-tau181, p-tau217: Phosphorylated tau fragments

Research Tools and Resources

Mouse Models

| Model | Description | Application |
|-------|-------------|-------------|
| APP/PS1 | Double transgenic | Amyloid pathology |
| 5xFAD | Five mutations | Aggressive AD model |
| APP knock-in | Humanized Aβ | Physiological model |
| APP KO | Complete knockout | Function studies |

Cell Lines

SH-SY5Y: Neuroblastoma, expresses APP
HEK293: Frequently used for APP processing studies
Primary neurons: Cortical and hippocampal cultures
iPSC-derived neurons: Patient-specific models

Clinical Considerations

Diagnosis

APP-related biomarkers inform AD diagnosis:

Decreased CSF Aβ42 correlates with plaque burden
Increased CSF sAPPβ indicates BACE1 activity
PET amyloid positivity precedes clinical symptoms

Treatment Response

Therapeutic efficacy is monitored through:

Amyloid PET reduction
CSF Aβ42 changes
Clinical outcome measures
ARIA monitoring for immunotherapy

Prevention

Given APP's central role, prevention strategies include:

Lifestyle modifications reducing vascular risk
Early amyloid detection
Potential prophylactic immunotherapy (in development)

Genetic Epidemiology

APP Mutations and Population Genetics

The APP gene shows significant variation across populations:

Pathogenic mutations: Over 50 pathogenic variants have been identified, predominantly in families with early-onset autosomal dominant AD. These mutations cluster around the secretase cleavage sites and Aβ coding region.

Risk variants: Genome-wide association studies have identified common variants near APP that influence AD risk:

SNPs in the APP promoter region affect expression levels
Variants in regulatory elements may modify risk
Population-specific effects require further study

APP copy number variation:

APP duplication causes autosomal dominant early-onset AD (ADAD)
Down syndrome (trisomy 21) provides natural model of APP overdose
Triplication alone is sufficient for Aβ deposition

Founder Effects

Several APP mutations show founder effects:

Swedish family: KM670/671NL mutation in large Swedish kindred
Volga German families: Multiple PSEN1 and APP mutations in families of German ancestry
British families: APP V717I mutation in British families with AD

Cellular Mechanisms

APP Trafficking and Processing

The subcellular localization of APP determines its processing pathway:

Secretory pathway: APP is synthesized in the endoplasmic reticulum and travels through the Golgi apparatus to the plasma membrane. Surface APP can be internalized and routed to endosomes where beta-secretase activity is highest.

Endosomal sorting: BACE1 localizes primarily to endosomes, making this compartment the primary site of amyloidogenic processing. The intracellular domain of APP contains sorting motifs that direct this trafficking.

Synaptic APP: At synapses, APP accumulates in pre-synaptic vesicles and is released activity-dependently, potentially serving as a signaling molecule.

Aβ Aggregation

The aggregation of Aβ into oligomers and plaques represents a critical pathological process:

Nucleation: Aβ monomers aggregate into oligomers, which serve as nuclei for further aggregation.

Oligomer toxicity: Soluble Aβ oligomers (rather than plaques) are considered the most toxic species, disrupting synaptic function and causing neuronal dysfunction.

Plaque formation: As aggregation proceeds, insoluble fibrils form and deposit as plaques. Plaques may represent a protective mechanism, sequestering toxic oligomers.

APP and Calcium Homeostasis

APP processing affects cellular calcium signaling:

Gamma-secretase cleavage releases the APP intracellular domain, which can influence calcium channel expression
Aβ can form calcium-permeable pores in membranes
Calcium dysregulation contributes to synaptic dysfunction

APP and Mitochondrial Function

Aβ accumulates in mitochondria and contributes to:

Mitochondrial dysfunction
Oxidative stress
Energy deficits
Apoptosis induction

Neuroimmunology

APP and Microglial Activation

The relationship between APP and microglia is bidirectional:

Microglial receptors for Aβ:

RAGE (Receptor for Advanced Glycation Endproducts) binds Aβ and triggers inflammation
TLR4 (Toll-like Receptor 4) recognizes Aβ and activates innate immunity
CD36 contributes to Aβ-induced inflammatory responses

Microglial clearance:

Microglia can phagocytose Aβ
TREM2 on microglia promotes Aβ clearance
Impaired clearance contributes to plaque accumulation

Inflammatory cytokines influence APP processing:

TNF-α increases BACE1 expression
IL-1β modulates APP transcription
Chronic inflammation may accelerate pathology

APP in Neuroinflammation

Aβ triggers inflammatory responses:

Cytokine release (IL-1β, IL-6, TNF-α)
Reactive oxygen species generation
Complement activation
Chronic neuroinflammation

Therapeutic Challenges

Lessons from Clinical Trials

The history of APP-targeted therapy provides crucial insights:

BACE1 inhibitor failures: The discontinuation of multiple BACE1 inhibitors due to cognitive worsening taught important lessons:

BACE1 has essential physiological functions
Complete inhibition is detrimental
Timing of intervention may be critical
Biomarker-driven patient selection needed

Immunotherapy successes and challenges:

Amyloid removal is achievable
Clinical benefit is modest
ARIA is a significant adverse effect
Early intervention may be more effective

Combination Therapy

Future approaches may combine:

Anti-amyloid and anti-tau therapies
Immunotherapy with small molecules
Targeting neuroinflammation
Symptomatic treatments

Personalized Medicine

Approaches to personalized APP-targeted therapy:

Genetic testing for APP mutations
Biomarker stratification
Age at intervention optimization
Polygenic risk scores

External Links

[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/351)
[Ensembl](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142192)
[OMIM](https://omim.org/entry/104760)
[UniProt](https://www.uniprot.org/uniprot/P05067)
[Allen Human Brain Atlas - APP](https://human.brain-map.org/microarray/search/show?search_term=APP)
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — 0.62 · Target: Cell-type-specific essential genes
[Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — 0.59 · Target: HTT, DMPK, repeat-containing transcripts
[Epigenetic Memory Reprogramming for Alzheimer's Disease](/hypothesis/h-29ef94d5) — 0.55 · Target: BDNF, CREB1, synaptic plasticity genes
[Cholesterol-CRISPR Convergence Therapy for Neurodegeneration](/hypothesis/h-a87702b6) — 0.55 · Target: HMGCR, LDLR, APOE regulatory regions
[Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — 0.53 · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
[Programmable Neuronal Circuit Repair via Epigenetic CRISPR](/hypothesis/h-9d22b570) — 0.45 · Target: NURR1, PITX3, neuronal identity transcription factors
[Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — 0.42 · Target: Disease-causing mutations with integrated reporters

Related Analyses:

[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving APP — Amyloid Precursor Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Associated Diseases

Als — associated with

[View disease page](/diseases/als)

ALS — associated with

[View disease page](/diseases/als)

Alzheimer — associated with

[View disease page](/diseases/alzheimer)

Alzheimer disease — causes

[View disease page](/diseases/alzheimer-disease)

Alzheimer's disease — associated with

[View disease page](/diseases/alzheimers-disease)

Alzheimer's Disease — causes

[View disease page](/diseases/alzheimers-disease)

Alzheimer'S Disease — biomarker for

[View disease page](/diseases/alzheimers-disease)

Amyotrophic Lateral Sclerosis — causes

[View disease page](/diseases/amyotrophic-lateral-sclerosis)

Autosomal Dominant Alzheimer's Disease — causes

[View disease page](/diseases/autosomal-dominant-alzheimers-disease)

dementia — associated with

[View disease page](/diseases/dementia)

Dementia — associated with

[View disease page](/diseases/dementia)

Familial Alzheimer's Disease — associated with

[View disease page](/diseases/familial-alzheimers-disease)

frontotemporal dementia — associated with

[View disease page](/diseases/frontotemporal-dementia)

Frontotemporal Dementia — causes

[View disease page](/diseases/frontotemporal-dementia)

Parkinson — associated with

[View disease page](/diseases/parkinson)

Parkinson's disease — associated with

[View disease page](/diseases/parkinsons-disease)

PARKINSON'S DISEASE — associated with

[View disease page](/diseases/parkinsons-disease)

Parkinson's Disease with Dementia — implicated in

[View disease page](/diseases/parkinsons-disease-with-dementia)

📖 View canonical wiki page →

Related Entities

APP

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-app
kg_node_id	APP
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8e432bc7b3c6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-app'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

150

Outgoing

268

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

APP — Amyloid Precursor Protein

APP — Amyloid Precursor Protein

Pathway Diagram

APP — Amyloid Precursor Protein

Pathway Diagram

APP — Amyloid Precursor Protein

Overview

Molecular Biology of APP

Gene Structure and Isoforms

APP Processing Pathways

Amyloidogenic Pathway (Aβ-Generating)

Non-Amyloidogenic Pathway (Aβ-Preventing)

Normal Physiological Functions

Synaptic Function and Plasticity

Neuronal Development

Metal Ion Binding and Homeostasis

Cell Adhesion and Signaling

Peripheral Tissue Functions

APP in Alzheimer's Disease

Amyloid Cascade Hypothesis

APP Mutations in Familial AD

Down Syndrome and APP

APP in Other Neurodegenerative Diseases

Cerebral Amyloid Angiopathy (CAA)

Parkinson's Disease

Traumatic Brain Injury

Other Disorders

Therapeutic Targeting

Secretase Modulators

Anti-Aβ Immunotherapy

APP-Targeting Approaches

Disease-Modifying Strategies

APP Family and Splice Variants

Brain Expression Pattern

Single-Cell Expression

Interaction Network

Biomarker Potential

APP Metabolites as Biomarkers

Research Tools and Resources

Mouse Models

Cell Lines

Clinical Considerations

Diagnosis

Treatment Response

Prevention

Genetic Epidemiology

APP Mutations and Population Genetics

Founder Effects

Cellular Mechanisms

APP Trafficking and Processing

Aβ Aggregation

APP and Calcium Homeostasis

APP and Mitochondrial Function

Neuroimmunology

APP and Microglial Activation

Inflammatory cytokines influence APP processing:

APP in Neuroinflammation

Therapeutic Challenges

Lessons from Clinical Trials

Combination Therapy

Personalized Medicine

See Also

External Links

Related Hypotheses

Pathway Diagram

Associated Diseases

💬 Discussion